AZD 1775

Drug Profile

AZD 1775

Alternative Names: AZD-1775; L001739996-008U; MK-1775 hemihydrate; MK1775

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Developer AstraZeneca; Merck & Co; National Cancer Institute (USA); Samsung Medical Center; University of Washington
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gynaecological cancer; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Phase I/II Solid tumours
  • Phase I Colorectal cancer; Haematological disorders; Head and neck cancer
  • Discontinued Cervical cancer

Most Recent Events

  • 02 Feb 2017 University of Birmingham and AstraZeneca plan a phase I trial for Head and neck cancer in United Kingdom (NCT03028766)
  • 18 Jan 2017 Phase-II clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03012477)
  • 05 Jan 2017 AstraZeneca suspended a phase I trial in Solid tumours (Late-stage disease, Monotherapy) in USA and Canada (NCT02482311)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top